Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash from Financing Activities (2020 - 2023)

Historic Cash from Financing Activities for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to $13.9 million.

  • Terns Pharmaceuticals' Cash from Financing Activities fell 8691.89% to $13.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $42.0 million, marking a year-over-year decrease of 7489.39%. This contributed to the annual value of $164.0 million for FY2024, which is 29092.04% up from last year.
  • As of Q4 2023, Terns Pharmaceuticals' Cash from Financing Activities stood at $13.9 million, which was down 8691.89% from $20000.0 recorded in Q3 2023.
  • Over the past 5 years, Terns Pharmaceuticals' Cash from Financing Activities peaked at $135.2 million during Q1 2021, and registered a low of -$1.6 million during Q2 2021.
  • Its 4-year average for Cash from Financing Activities is $28.6 million, with a median of $797000.0 in 2021.
  • In the last 5 years, Terns Pharmaceuticals' Cash from Financing Activities crashed by 10941.57% in 2021 and then surged by 66221250.0% in 2022.
  • Terns Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $68.6 million in 2020, then plummeted by 99.98% to $16000.0 in 2021, then skyrocketed by 662212.5% to $106.0 million in 2022, then crashed by 86.92% to $13.9 million in 2023.
  • Its last three reported values are $13.9 million in Q4 2023, $20000.0 for Q3 2023, and $489000.0 during Q2 2023.